Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial aims to determine whether Meu-cinn promotes gastric mucosal health in adults with functional dyspepsia and to assess its safety.
The main questions are:
Researchers will compare Meu-cinn to placebo to evaluate their effectiveness in promoting gastric mucosal health.
Participants will:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Meu-cinn group | Experimental | This group takes Meu-cinn for 8 weeks. |
|
| Placebo group | Placebo Comparator | This group takes placebo for 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Meu-cinn | Dietary Supplement | Meu-cinn 250 mg/day for 8 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| The Korean version of the Gastrointestinal Symptom Rating Scale, Total score | Measured at baseline and 8 weeks. This is a 4-point Likert scale for each of the 15 items, with scores ranging from 0 to 3. A score of 0 indicates no symptoms, and 3 represents very severe symptoms. The higher the overall score, the more severe the gastrointestinal symptoms. The minimum value was 0, and the maximum value was 45, and higher scores mean a worse outcome. | From enrollment to the end of treatment at 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| The Korean version of the Gastrointestinal Symptom Rating Scale, Subtotal score of upper abdomen | Measure at baseline, 1, 2, 4, and 8 weeks. This is a 4-point Likert scale for each of the 8 items, with scores ranging from 0 to 3. A score of 0 indicates no symptoms, and 3 represents very severe symptoms. The higher the overall score, the more severe the gastrointestinal symptoms. The minimum value was 0, and the maximum value was 21, and higher scores mean a worse outcome. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sang Yeoup Lee, Professor, MD, PhD | Contact | 82+55-360-2860 | drsaylee@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Sang Yeoup Lee, Professor, MD, PhD | Pusan National University Yangsan Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pusan National University Yangsan Hospital | Recruiting | Yangsan | 50612 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Dietary Supplement |
Placebo 250 mg/day for 8 weeks |
|
| From enrollment to the end of treatment at 8 weeks |
| Patient's global assessment score | The 5-point Likert scale for the Patient's Global Assessment Score is a self-reported tool where patients rate their disease activity. It uses an order scale, with 5 indicating "Very Good" and 1 indicating "Poor." The patient evaluates their condition based on this scale: Very Good-Good-Fair-Unchanged-Poor | From enrollment to the end of treatment at 8 weeks |
| Visual Analogue Scale for evaluating gastric mucosal improvement | Measured at baseline and 8 weeks. The minimum value was 0 and the maximum value was 100, and higher scores mean a worse outcome. | From enrollment to the end of treatment at 8 weeks |
| Gastrointestinal symptom score | Measured at baseline and 8 weeks. The minimum value was 0 and the maximum value was 40, and higher scores mean a worse outcome. For each gastrointestinal symptom, the minimum value was 0, and the maximum value was 4, and higher scores mean a worse outcome. | From enrollment to the end of treatment at 8 weeks |
| Pepsinogen I level (ng/mL) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| Pepsinogen II level (ng/mL) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| Pepsinogen I/Pepsinogen II ratio | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| Gastrin-17 level (ng/L) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| High-sensitive C-reactive protein (mg/dL) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| Immunuglobulin G (mg/dL) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| Immunoglobulin A (mg/dL) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| Immunoglobulin M (mg/dL) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| The derivatives of reactive oxidative metabolites (CARR U) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |
| Biological antioxidant potential (u M) | Measured at baseline and 8 weeks | From enrollment to the end of treatment at 8 weeks |